The risk of flu infections in cancer patients who are at highest risk for influenza can be reduced by a new vaccine strategy.
Even though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.
The Yale Cancer Center researchers' strategy entails offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.
Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group of patients at high risk for infection, Branagan said. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.